cGAS-STING pathway in cancer biotherapy

Y Wang, J Luo, A Alu, X Han, Y Wei, X Wei - Molecular cancer, 2020 - Springer
The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor
immunity by generating type I interferons. In recent decades, we have witnessed that …

Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy

L Motedayen Aval, JE Pease, R Sharma… - Journal of clinical …, 2020 - mdpi.com
Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have
been effective in only a small subset of patients and a principal mechanism underlying …

Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles

P Dosta, AM Cryer, MZ Dion, T Shiraishi… - Nature …, 2023 - nature.com
Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity

L Hou, C Tian, Y Yan, L Zhang, H Zhang, Z Zhang - ACS nano, 2020 - ACS Publications
Cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) are essential
components of the innate immune sensors to cytosolic DNA and elicit type I interferon (IFN) …

[HTML][HTML] STING activation in cancer immunotherapy

T Su, Y Zhang, K Valerie, XY Wang, S Lin, G Zhu - Theranostics, 2019 - ncbi.nlm.nih.gov
Cancer immunotherapy modulates and leverages the host immune system to treat cancer.
The past decade has witnessed historical advancement of cancer immunotherapy. A myriad …

Chemical strategies to boost cancer vaccines

WH Li, YM Li - Chemical reviews, 2020 - ACS Publications
Personalized cancer vaccines (PCVs) are reinvigorating vaccine strategies in cancer
immunotherapy. In contrast to adoptive T-cell therapy and checkpoint blockade, the PCV …

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm …

J Wei, X Lu, Q Liu, Y Fu, S Liu, Y Zhao, J Zhou… - Nature …, 2023 - nature.com
In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …

Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment

Q Chen, L He, X Li, L Xu, T Chen - Biomaterials, 2022 - Elsevier
Discovery of effective chemical sensitizers to synergize with natural killer cells
immunotherapy is urgently desired to overcome its unsatisfactory efficacy in clinic. Herein …

CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes

A Kosaka, K Ishibashi, T Nagato, H Kitamura… - Journal of Experimental …, 2021 - rupress.org
Activation of STING signaling plays an important role in anti-tumor immunity, and we
previously reported the anti-tumor effects of STING through accumulation of M1-like …

The age of cyclic dinucleotide vaccine adjuvants

H Gogoi, S Mansouri, L Jin - Vaccines, 2020 - mdpi.com
As prophylactic vaccine adjuvants for infectious diseases, cyclic dinucleotides (CDNs)
induce safe, potent, long-lasting humoral and cellular memory responses in the systemic …